Skip to content
Company Analysis

AbbVie Inc. ABBV

A comprehensive view of key metrics, scores, and financial health for AbbVie Inc.

Overview of AbbVie Inc.

ABBV NYQ
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Mega Cap
AbbVie Inc. (ABBV), is a Mega Cap company, in the Drug Manufacturers - General industry, last closed at $263.20, about 71.7% overvalued vs fair value, +39.0% 1Y return, placing in the top 25% of its sector.
Metrics P/E 95.9× Rev Growth 8.6% ROE 15367.3% Gross Margin 70.2% Div Yield 2.89%
USD 263.20
2.45%
(Delayed)
• Vol 90d: 28.7%
52-Week Range
Market Cap
$441.54B
Enterprise Value
$505.01B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Good
Valuation
Fair
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Good
Valuation
Fair
Completeness: 82%
Confidence: 86%
Updated: Jul 5
Top Beats

Quick Facts

Website https://www.abbvie.com
HQ North Chicago, IL
Employees 57,000
Fiscal year Dec 31

Next Events

Earnings Jul 30

Fair Value Snapshot

Bear Base Bull
$68
$75
$82
Current: $263.20 -72% vs base

Engine Room Money Flow™

Mega Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
56.33B
8.6%%
Gross Profit
39.43B
8.9%%
R&D Expense
12.79B
-28.9%%
Operating Income (EBIT)
6.52B
45.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
200.5%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$12.6B
70.9% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
3
Active Leaks
0/3
Improving
1
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating AbbVie Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
69
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
72
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing ABBV's balance between Growth (26.2%), Profitability (46.6%), and Safety (27.3%). Growth 26% Safety 27% Profitability 47%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

45th percentile vs peers
46
Key Signals
Rev Growth YoY 8.6% 63p Revenue CAGR 3Y 1.8% 41p TSR 32.3% 68p EPS Growth YoY -1.2% 30p EPS CAGR 3Y -29.0% 22p
Strengths
  • D/E Ratio in top 20% of peers (-20.64, 98th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Operating Margin in top 20% of peers (32.9%, 93th percentile)
  • ROIC in top 20% of peers (20.0%, 90th percentile)
Risks

No significant risks identified for this axis.

Profitability

81th percentile vs peers
81
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

47th percentile vs peers
47
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for AbbVie Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$74.50
- - -
-71.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000